Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

MIRACLE of LIFE Study

NCT06074601 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1. Can cell-free RNA-based biomarkers predict which pregnant people are at greatest risk of developing adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)? 2. What is the performance of such biomarkers when predicting an adverse pregnancy outcome (e.g., sensitivity, specificity, PPV, NPV, TPR)?

Interventions

  • DIAGNOSTIC_TEST Mirvie Predictive Test for Adverse Pregnancy Outcomes

Study Locations (10)

Pennsylvania

  • Thomas Jefferson University — Philadelphia
  • University of Pittsburgh Medical Center — Pittsburgh

California

  • University of California San Diego — San Diego

Florida

  • Women's Care Florida — Orlando

Louisiana

  • Ochsner Health System — New Orleans

Massachusetts

  • Beth Israel Deaconess Medical Center — Boston

Missouri

  • Washington University School of Medicine — St Louis

Ohio

  • The Ohio State University — Columbus

Texas

  • University of Texas Medical Branch — Galveston

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2021-08-01
Est. Completion 2025-12-31

Sponsor

Mirvie

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06074601

The ClinicalTrials.gov registry entry for NCT06074601 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirvie, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 10 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention — of which Mirvie Predictive Test for Adverse Pregnancy Outcomes is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06074601 reports 10 study locations spanning 9 distinct geographic areas — top geographies include Pennsylvania, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06074601 about?

NCT06074601 is a clinical study titled "MIRACLE of LIFE Study". The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1. Can cell-free RNA-based biomarkers predict which pregnant people are at ...

What is the current status of trial NCT06074601?

This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2021-08-01. Estimated completion is 2025-12-31.

What conditions does trial NCT06074601 study?

This clinical trial studies the following conditions: Preeclampsia, Preterm Birth, Gestational Hypertension, Gestational Diabetes Mellitus in Pregnancy, Preterm Labor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06074601?

The interventions under investigation include: Mirvie Predictive Test for Adverse Pregnancy Outcomes (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06074601?

This trial is sponsored by Mirvie, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06074601 being conducted?

This trial has 10 study locations across California, Florida, Louisiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial